Table 2. Association of CIMP status and survival among CRC patients.

		Overall survivala			Disease-specific survivala
Factor	N	Deaths (%)	HR	95% CI	Deaths (%)	HR	95% CI
CIMP-L/N	1170	330 (28)	1.00	Reference	254 (22)	1.00	Reference
CIMP-H	187	52 (28)	1.00	0.72–1.40	35 (19)	0.96	0.65–1.41
Female
CIMP-L/N	482	142 (29)	1.00	Reference	109 (23)	1.00	Reference
CIMP-H	104	29 (28)	1.22	0.77–1.95	24 (23)	1.24	0.74–2.08
Male
CIMP-L/N	688	188 (27)	1.00	Reference	145 (21)	1.00	Reference
CIMP-H	83	23 (28)	0.88	0.54–1.44	11 (13)	0.65	0.34–1.27
Age ⩽68 years
CIMP-L/N	584	132 (23)	1.00	Reference	115 (20)	1.00	Reference
CIMP-H	68	15 (22)	0.93	0.53–1.66	13 (19)	0.96	0.52–1.76
Age 69+ years
CIMP-L/N	586	198 (34)	1.00	Reference	139 (24)	1.00	Reference
CIMP-H	119	37 (31)	1.15	0.75–1.75	22 (18)	1.09	0.65–1.86
Proximal location
CIMP-L/N	360	105 (29)	1.00	Reference	78 (20)	1.00	Reference
CIMP-H	121	34 (28)	1.33	0.83–2.15	20 (17)	1.03	0.57–1.86
Distal locationb
CIMP-L/N	810	225 (28)	1.00	Reference	176 (22)	1.00	Reference
CIMP-H	66	18 (27)	0.77	0.47–1.27	15 (23)	0.81	0.47–1.41
Stages I and II
CIMP-L/N	600	94 (16)	1.00	Reference	49 (8)	1.00	Reference
CIMP-H	108	16 (15)	0.71	0.37–1.36	6 (6)	0.41	0.14–1.20
Stage III
CIMP-L/N	405	107 (26)	1.00	Reference	83 (20)	1.00	Reference
CIMP-H	56	16 (29)	1.30	0.70–2.40	10 (18)	1.09	0.51–2.30
Stage IV
CIMP-L/N	165	129 (78)	1.00	Reference	122 (74)	1.00	Reference
CIMP-H	23	20 (87)	1.15	0.69–1.94	19 (83)	1.18	0.69–2.00

Abbreviations: CI= confidence interval; CIMP=CpG island methylator phenotype; CIMP-H=CIMP-high; CIMP-L/N=CIMP-low/negative; CRC=colorectal cancer; HR=hazard ratio.

^aAdjusted for age, sex, education level, alcohol, tumour location, cancer stage, number of invaded lymph nodes, use of hormone replacement therapy, chemotherapy, microsatellite instability and BRAF mutation; additional adjustment for time-dependent effects of age and chemotherapy.

^bFrom the splenic flexure, including the rectum.